Mathai Mammen

Insider Reports History

Location
South San Francisco, CA
Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact for Mathai Mammen
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Mathai Mammen:

Company Role Class Num Shares Value Price $ Report Date Ownership
JOHNSON & JOHNSON EVP, Pharm, R&D Common Stock 41,934 $7,212,648 $172.00 15 Feb 2022 Direct
10x Genomics, Inc. Director Class A Common Stock 180,259 $4,380,943 $24.30 11 Jun 2024 Direct
JOHNSON & JOHNSON EVP, Pharm, R&D Employee Stock Options (Right to Buy) 38,736 $2,809,909 $72.54 14 Feb 2022 Direct
JOHNSON & JOHNSON EVP, Pharm, R&D Restricted Share Units 3,922 $613,126 $156.33 14 Feb 2022 Direct
JOHNSON & JOHNSON EVP, Pharm, R&D Performance Share Units 737 $116,004 $157.40 15 Feb 2022 Direct
10x Genomics, Inc. Director Stock Option (right to buy) 4,661 14 Jun 2023 Direct

Insider Reports Filed by Mathai Mammen

Symbol Company Period Transactions Value $ Form Type Role Filing Time
TXG 10x Genomics, Inc. 11 Jun 2024 1 $0 4 Director 13 Jun 2024, 16:22
TXG 10x Genomics, Inc. 14 Jun 2023 2 $0 4 Director 16 Jun 2023, 17:40
TXG 10x Genomics, Inc. 11 May 2023 3 -$1,511,086 4 Director 15 May 2023, 16:37
TXG 10x Genomics, Inc. 15 Jun 2022 2 $0 4 Director 17 Jun 2022, 17:14
JNJ JOHNSON & JOHNSON 14 Feb 2022 5 +$5,867,529 4 EVP, Pharm, R&D 17 Feb 2022, 05:00
JNJ JOHNSON & JOHNSON 14 Feb 2022 3 -$394,265 4 EVP, Pharm, R&D 15 Feb 2022, 19:03
JNJ JOHNSON & JOHNSON 03 Jan 2022 0 $0 3 EVP, Pharm, R&D 13 Jan 2022, 15:43
TXG 10x Genomics, Inc. 11 Jun 2021 2 $0 4 Director 15 Jun 2021, 17:50